Ewing's sarcoma family tumors (EFT) are characterized by specific chromosomal translocations, which lead to EWS/ETS transcription factors. Elucidation of EWS/ETS target gene networks within the context of other signaling pathways, together with the identification of the initiating cell, and the development of genetically engineered mice will hopefully lead to biology-based therapeutic strategies for these tumors.
Introduction
Research into the molecular biology of Ewing's sarcoma (ES) has increased enormously over the last few years, and a large body of knowledge is now available. Despite these efforts, our understanding of the mechanisms responsible for the disease is only advancing slowly. Here we review the most recent insights into the origins of ES pathogenesis, focusing on the critical points that may be hindering the progress in the field, namely: the basis of gene and protein regulation networks initiated by the chimeric protein, the proposed direct and indirect targets, and the pathways they are involved in; sarcomagenesis, with the clarification of the cell of origin, and its extrapolation to the construction of animal models absent in ES research; the future promises of investigation in tumor immunology; and finally the translation of such a large volume of information from researchcontributed developments into the preclinical field of drug assays.
Chromosomal Translocations in Ewing's Sarcoma Family Tumors: Significance and Singularity
Ewing's sarcoma family tumors (EFT), such as ES and primitive neuroectodermal tumor, are an uncommon group of cancers that arise in mesenchymal tissues. They occur in pediatric or young adult patients, and they represent the second most common malignant bone neoplasm after osteosarcoma (one to three cases per million people/year).
Singular gene fusions. The EFT family comprises morphologically and clinically heterogeneous tumors, mainly small round cell neoplasms, which are characterized by nonrandom balanced chromosomal translocations involving the EWS gene and one of several members of the ETS family genes; mainly FLI1 (90-95%) and ERG (5-10%), but also FEV, ETV1, and ETV4 (<1%; ref. 1) . Recently, a reciprocal insertion-inversion-translocation mechanism has been described in ES, alternatively to the classical reciprocal translocation. This mechanism induces a balanced EWS/ERG fusion gene, although its complexity would account for its low incidence in cases of ES (2) .
Combinations of EWS and ETS family genes are unique for ES (Table 1A) , although other EWS rearrangements participate in different pathologies (Table 1B) . Accordingly, the partner gene rather than EWS itself, seems to specify the tumor type. The assumed rule that specific translocations induce specific phenotypes is challenged, however, by numerous exceptions to the same translocation present in different clinicopathological entities (Table 1C) . Because in some cases translocations are not sufficient for cell transformation, dissimilar differentiation programs in the tumoral progenitor cells or even the presence of secondary events may help to explain why the same translocation is related to completely different tumors (3) .
Variants in EWS/ETS fusions also differ in the location of the breakpoint. Some studies have revealed that at prognosis differences between fusion types could exist, and that different transactivation activities would apply for different gene fusions. However this issue needs further clarification, because such differences have not been found in multicentric prognostic studies and their biological bases remain unclear (4) .
EWS/ETS chimeric proteins. The t(11;22)(q24;q12) translocation is the most common, suggesting that its product lies in the origin of these malignancies (5) . EWS protein (TET family; Fig. 1 ) is predicted to be an RNA-binding protein containing the transcriptional activation domain(s) in the N-terminus and the RNA recognition motif in its C-terminus (6) . It has been reported that EWS may function as a transcription factor. In addition, it is expressed ubiquitously throughout the cell cycle, and its mRNA has a long half-life. FLI1 is a transcription factor (ETS family) that activates specific genes through their DNA-binding regions; usually at their C termini (7) . Target genes include oncogenes, tumor suppressor genes, and genes related to apoptosis, differentiation, angiogenesis, and invasion (8) .
The translocation fuses EWS(22q12) to FLI(11q24) in-frame, leading to EWS/FLI1 on der (22) . This encodes an oncoprotein, consisting of the EWS N-terminus and the C-terminus DNA-binding domain of FLI1, with new transcriptional activation potential due to the replacement of the inactive transcriptional domain of FLI1 by the N-terminus of EWS. At least eight fusion types have been sequenced, depending on the breakpoints in the FLI1 and EWS exons, with prevalence of type-1 (EWS.exon.7/FLI1.exon.6).
In addition to the aforementioned insertion-inversion-translocation mechanism involving chromosomes 19, 21, and 22, which fusions EWS to EGR (2), new and rare rearrangements have recently been reported in EFT-like tumors:
1 EWS fuses (68) to zinc-finger genes POU5F1, PATZ1, rendering chimeras with a probable transcriptional activator function. Interestingly, recent cytogenetic analyses have identified new rare translocations involving 22q12 (EWS fused to NFATc2), which amplify the spectrum of the morphology and rearrangements in ES. Furthermore, uncommon fusions not involving EWS (BRD4/NUT, CIC/ DUX4) trigger molecular changes similarly to EWS/ETS fusions. Taken together, these data reveal new variants of EFT and point to the difficulties in making correct differential diagnoses.
What are the functions of EWS/ETS proteins? Chimeric proteins in ES condition the specificity in pathogenesis and maintenance of sarcoma that characterizes the disease. Owing to the combined action of the EWS transcriptional activator and the FLI1 DNA-binding domain, they function as either aberrant transcription factors or potent repressors, or by altering RNA processing. They localize to the nucleus, bind DNA in a site-specific manner, and act as potent transcriptional modulators, usually as activators to mediate oncogenesis, although sometimes repressing more genes than they up-regulate.
Alteration in either the EWS transcriptional domain (6), or the ETS DNA-binding domain (9) , restricts their transformation potential, suggesting that the transcriptional activation function lies in the EWS domain. EWS/ETS proteins also require the collaboration of additional proteins to perform their functions (AP-1, Fos-Jun, RNA helicase-A; ref. 10).
Additionally, EWS/FLI1 engages in post-transcriptional processes: in vitro it behaves as an aberrant RNA-splicing factor by blocking U1C-, TASR-, and YB1-mediated splicing. EWS/FLI1 interferes with normal EWS in the recruitment of EWS-binding proteins, uncoupling gene transcription from RNA-splicing, and consequently causing malignant transformation in ES.
Secondary events. The relevance of secondary mutations, which could be of relevance in the biology of ES, is usually shadowed by translocations. Losses of p16INK4A and mutations of p53 have been documented correlating with a poorer prognosis, similarly Figure 1 . Structural features of the EWS/FLI1 chimeric protein, together with the native proteins from which it arises. The EWS N-terminal domain contains amino acidic residues 1 to 264 at a minimum, 31 degenerate hexapeptide repeats (DHR), as well as seven Tyr residues. Secondary structures (T-L-T/S-T-S) have both activating and regulatory functions, and may be responsible for protein-protein interactions. The C-terminal domain has a distinctive conserved 87-amino-acid RNA recognition motif-ribonucleoprotein consensus sequence motif (the RRM/RNP domain), commonly found in most RNA-binding proteins, and it has a number of RGG (arginine-glycine-glycine) repeats that also seem to facilitate binding to single-stranded nucleic acid. FLI1 is a transcription factor, with a naturally occurring transactivating region in the N-terminal end, and a C-terminal transactivating domain (CTA), which encloses a highly conserved, sequence-specific, ETS-type DNA-binding domain. The chromosomal t(11;22)(q24;q22) translocation in ES results in the fusion of the N-terminal domain of EWS and the DNA-binding domain of FLI1, generating the oncoprotein EWS/FLI1. The transactivating domain of EWS is retained, whereas the RNA-binding domain is lost and is replaced by the sequence-specific DNA-binding domain of the FLI1 protein. The type-1 chimeric protein is represented entirely schematically, with the junction between the two segments taking place at amino acid positions 264 and 219 in EWS and FLI1, respectively. Type-2 or -3 can be deduced from type-1 by the insertion of 22 or 84 additional amino acids from FLI1 or EWS, respectively. to the deletion of CKDN2A at 9p21.3 (11) . Recently, several groups, including ours, 2,3 have identified different gains and losses on various chromosomes, usually consisting of gains of chromosomes 1q, 2, 8, and 12; and deletions of 1p, 9p, and 16q. These are associated with a poorer prognosis in cases with more than three abnormalities (12) . Additionally, that study suggested that a duplication of der (22) after translocation is a common event in ES. Telomere-length reduction has also been related to genomic instability and prognosis.
Moreover, in a recent study the induction of EWS/FLI1 alone elicited phenotypic and transcriptional changes but did not transform human mesenchymal stem cell (MSC), suggesting that translocation is necessary, but not sufficient, to induce tumor formation (13) . Thus, secondary events in ES could be of relevance, not only for prognosis but also for creating an adequate background for translocation and/or allowing fusion genes to transform the cell.
Elucidation of EWS/ETS Targets
The identification of EWS/FLI1 genomic and proteomic targets (direct and indirect) provides a major strategy toward gaining an (15) . Other interacting genes are involved in signaling pathways and gene regulation networks initiated by EWS/ FLI1, although these genes are not direct targets (Table 2) .
Nevertheless, although proteins are the actors and key targets of translocations, research into ES lacks extensive studies on proteomics. Our laboratory has recently studied the inactivation of EWS/FLI1 in a shRNAi model and found differences in protein expression and post-translational modifications (PTM); mainly for nuclear proteins, cell cycle regulators, and metabolism (Table 2) . 5 In conclusion, EWS/FLI1 controls different routes of tumor development, maintenance, and progression in ES, namely: cell proliferation and survival (activation of targets IGF1, MYC, NKX2.2, TOPK); escape from growth inhibition, senescence, and apoptosis (inhibition of p21, p57kip, TGFBR2, IGFBP3); and the up-regulation of critical genes involved in neural tube and neural crest development (NKX2.2, CCK).
Signaling Pathways in ES
Scrutiny of the cellular routes altered in ES, and in particular of the changes in surface adhesion molecules, receptor tyrosine kinases, growth factors, and transcription factors, seems to be a promising strategy to identify potential candidates for therapeutic intervention and diagnostic development (Fig. 2) .
Tyrosine kinase pathways. EFT proliferation and maintenance is determined by the autocrine and paracrine activation of growth factor receptors and their corresponding ligands, such as insulinlike growth factor 1 (IGF1; ref. 16 ). Targeting of EWS/FLI1 by RNA interference in ES cells affected IGF1/IGF1R survival pathway (17) and its downstream targets (14) . Both mitogen-activated protein kinase (MAPK) and PI3K signaling pathways are constitutively activated in ES, probably because of the presence of IGF1R-mediated autocrine loops. By analyzing gene expression in 181 tumor types, including 16 classes of sarcomas, a stringent clustering was observed, with high expression levels of tyrosine kinases or receptor tyrosine kinases in the pediatric sarcomas group (18) .
Wnt pathways. Recent evidence has shown that Wnt/Frizzled signaling is functional in ES lines (19) . Canonical Wnt/h-catenin signaling enhances EFT cell motility, contributing to metastasis, probably through either autocrine or paracrine modes of action of Wnt glycoproteins, because these are expressed in bone, muscle, and soft tissues. Wnt-3a induces morphological changes characterized by the formation of long cytoplasmic extensions in EFT cells.
Interactions between ES and the Immune System: Implications for Immunotherapy
Identification of the molecular mechanisms of interaction between cancer and the immune system and their significance in immunotherapy is an exciting field that has lately aroused increasing interest in the context of ES. Both specific antibodies and cellular immunotherapy may, in the future, afford new therapeutic options in ES. Preclinical and phase I clinical studies using both small kinase inhibitors and antibodies have shown the relevance of the inhibition of the IGF1-receptor. This strategy also seems to be relevant to overcome the resistance to conventional therapeutic drugs (reviewed in ref. 20) .
Other preclinical studies have reported the potential efficacy of using cytotoxic effector cells to eliminate ES cells. Human leukocyte antigen (HLA) expression plays a central role in the identification of tumoral cells by the cytotoxic effector cells. However, tumors can escape recognition by down-regulating HLA class I loci or alleles. A low or null expression of both class I and II HLA has recently been documented in ES tumors, mostly related to lung metastases and advanced stages of disease. Accordingly, knowledge about HLA in ES is essential in designing new cellular Figure 3 . Conditional GEM models of sarcomas. To engineer GEM models, two different mouse strains must be generated previously: loxP-mice and Cre-mice. LoxP mice harbor the fusion gene (FG). 1, The conditional transgenic model makes use of a DNA construct that is randomly integrated into the mouse genome. This DNA harbors a promoter (P) and a stop-cassette (+Stop), flanked by loxP sites (depicted as yellow triangles) upstream from the fusion gene (FG). When loxP mice harboring the type-1 EWS/FLI1-loxP allele were crossed with Prx1-Cre mice, the descendants develop poorly differentiated sarcomas. 2, In contrast, in the conditional loxP-Stop-loxP knock-in model the target vector contains ''homology arms'' complementary to specific genomic regions, which allows specific integration into the mouse genome. When loxP mice harboring the EWS/FLI1-loxP allele were crossed with Mx1-Cre mice, the resulting animals developed leukemia but not ES. 3, The conditional invertor model makes use of a floxed cassette harboring both a positive selectable marker (+1) and a cDNA sequence of one of the fusion partners (FG2), which is orientated opposite to the direction of transcription of the target gene (FG1). After the expression of Cre recombinase the cassette is inverted, and the fusion gene is then generated. This methodology was used to induce the expression of EWS/ERG. 4, The conditional translocator model is an interesting approach that has not been used to induce the expression of any ES fusion gene so far. LoxP sites are introduced in each of the two wild type genes (FG1 and FG2), which then form the fusion gene. This approach was used to induce the expression of the MII/Enl fusion gene characteristic of leukemia. Thick black bars represent homology arms. (+1), (+2) depict positive selectable markers. Red boxes represent a negative selectable marker that is eliminated after gene targeting in embryonic stem cells. FG1* and FG2* represent the exons of the FG1 and FG2, respectively, which coparticipate the fusion gene. These exons are included in the homology arms.
immunotherapeutic approaches (21) . Moreover, tumoral cells can be eradicated by apoptosis induced by natural-killer (NK) cells or cytotoxic T-lymphocytes, mainly through the death-receptor and the perforin-granzyme pathways, in which caspases play a central role. However, tumoral cells avoid apoptosis through expression of specific antiapoptotic proteins (cellular FLICE-inhibitory protein, serine protease inhibitor-9). Furthermore, ES cells are selectively resistant to the cytolytic death-receptor pathway, while retaining their sensitivity to the perforin-granzyme pathway (22) . More recently, the cytolytic activity of NK cells has been shown to depend critically on the NKG2-D and DNAM-1 pathways, and that cytokine IL15-activated NK cells are more efficient at recognizing ES cell lines than resting NK cells. Thus, although further studies are needed, these data indicate that immunotherapy based on NK cells could be feasible in ES.
Which Cells Originate ES?
The elucidation of the cell of origin is a crucial issue for discovering the mechanisms involved in the genesis of EFT, and also for the identification of reliable molecular markers and possible therapeutic targets. The cellular context contributes to the phenotype, because the introduction of EWS/ETS fusions into different cellular models results in diverse outcomes ranging from the induction of cell cycle arrest, or apoptosis, to dedifferentiation (23, 24) . This suggests that EWS/FLI1 is a potent differentiation factor that blocks a preexisting commitment, at the same time imposing neural differentiation.
The expression of neural markers in EFT points to either a potential mesenchymal or a neuroectodermal origin. In a recent study, the profiles of different EWS/FLI1-silenced ES cell lines converged toward a ''core'' EWS/FLI1 transcriptional signature that was correlated with published MSC data, supporting the notion that MSC would be the candidates to be the ES precursor cells (25) . Nevertheless, EWS/FLI1 up-regulates critical genes in neural crest development, acting as a cell lineage determinant, rather than a pure ''oncogene'' (26) . The EWS/FLI1 fusion protein can transform primary bone marrow-derived mesenchymal cells to form ES-like tumors in mice (27) . Moreover, EWS/FLI1 induces murine MSC transformation even in the absence of other prooncogenic events, suggesting that its generation would be the initiating event in EFT pathogenesis. Nonetheless, as pointed out before, the induction of EWS/FLI1 does not transform human MSC, suggesting the involvement of additional alterations (13) . This highlights the importance of the research on MSC (or even earlier precursor cells), whose developmental program is deranged and blocked early on in differentiation, in the search for specific molecular markers that are able to describe the ontogeny of the disease, and allow the early detection of cells involved in sarcomagenesis.
Searching for a Genetically Engineered Model for ES
As seen above, in EFT research, in which the prevalence is low, the lack of a proper animal model to study both EWS/FLI1 targeting and the influence of the cellular background has hampered the clarification of essential unsolved questions.
From cell culture to mouse models. Culture studies have provided important information on ES research. However, in vitro conditions exert selective pressure on cells, determine molecular mutations, hinder angiogenesis and metastases, and lack the microenvironment that plays so crucial a role in ES.
The development of animal models in ES is, therefore, a fundamental issue.
Several xenogeneic models of human origin have been reported. They have been used to test new drugs (the National Cancer Institute used four ES xenografts to identify new active drugs against childhood cancers), and to gain knowledge about the pathogenesis of ES. Moreover, several specific ES metastatic models have been developed in mice. However, they face many problems: the tissue architecture is altered, genetic heterogeneity is diminished, and the course of human disease is not accurately reflected. Accordingly, xenograft models, which are an intermediate step between cell culture and murine cancer models, should be more properly considered as ''animal cultures'' (28) .
Genetically engineered models. So far, no genetically engineered models (GEM) have been developed for ES, probably because the expression of the fusion gene causes embryo lethality. Differences in genetic background, pathway activation, binding sites, coregulators, etc., between humans and mice create additional problems. To circumvent this, EWS/FLI1 should be expressed exclusively in MSC, after previous identification of specific mesenchymal genes, to avoid EWS/FLI1 expression in hematological tissues (it causes leukemia; ref. 29) .
To date, different GEM of sarcomas have been developed, with problematic results in same cases. In its simplest version, transgenic GEM mice were generated by pronuclear injection of cDNA under the control of ubiquitous promoters (liposarcoma with FUS/CHOP; ref. 30) . Recently, a conditional transgenic GEM was created by inducing type-1 EWS/FLI1 expression in the primitive MSC of the embryonic limb buds, making use of specific recombinases (Cre-Lox system) that allow spatio-temporal control of the chimeric gene. However, it did not induce tumor formation but did elicit several limb defects. Only in a setting of p53 deletion did animals develop poorly differentiated sarcomas but not ES (31) . In contrast, conditional knock-in mice were created by utilizing gene targeting methodologies in embryonic stem cells and specific recombinases ( Fig. 3; ref. 29) . However, although this approach generated a EWS/FLI1 GEM, its expression did not cause ES tumors but, instead, myeloid-erytroid leukemia and animal death. In alveolar rhabdomyosarcoma, p16INK4A and p53 pathways had to be inactivated to produce the expected phenotype (32) . In synovial sarcoma, the expression of the chimeric gene in cells other than myoblasts generated myopathy or embryonic lethality (33) . These findings all indicate the relevance of correct selection of the target cell in which the fusion gene should be expressed.
An alternative strategy generated T-cell lymphomas by conditional expression in hematopoietic cells of EWS/ERG, a characteristic ES fusion gene. The authors used an ''invertor model'' (a new version of the knock-in strategy using loxP sites), in which the target gene is oriented in the reverse direction for transcription (34) .
Future Perspectives for EFT Treatment
A number of conceptually important questions remain to be answered: why, how, and when do chromosome aberrations originate? Is the cellular context the only determinant cause that instigates sarcoma development under specific circumstances? Are the resulting gene fusions sufficient for tumorigenesis and, if not, what is the pathogenetic relationship between these rearrangements and the other genetic and epigenetic alterations that characterize neoplastic cells?
The discovery of the cell of origin is an urgent goal. It is crucial to generate real ES models in order to unravel the signaling pathways that occur in initiation and progression, and to clarify the links with secondary alterations, all of them essential for understanding the genesis and progression of ES. The mechanisms eliciting the EWS/ETS rearrangements are also unknown. However, these translocations must be the result of the physical interaction of the partner genes in the nucleus. Presumably, the migration and close relocation of both translocation partners at a shared transcription factory would facilitate such translocations (35) .
Proteomics should also allow us to delineate the pathways affected by the malfunction of ES chimeric proteins. Proteomic approaches can help to monitor changes in abundance, differentiation patterns, and PTM associated with chimeric proteins. Because the function of the chimera determines the onset of the sarcomagenesis, proteomic analyses seem central for the study of EFT. Additionally, a comprehensive characterization of the molecular structure of the fusion proteins would unravel their mechanisms, thereby facilitating the assessment of structure-function relationships. In the future, this should provide clues for developing ES protein-specific inhibitors with therapeutic potential (1) . Moreover, the epigenetic regulation of gene expression is partially mediated by PTM of histones, which in turn modulate chromatin structure, thus conditioning the ''cellular state.'' Chromatin immunoprecipitation sequencing studies of the MSC of ES patients could identify new potential regulatory elements, possibly involved in the translocation event, and could therefore reveal the mechanisms triggering genetic instabilities in ES cells.
The discovery of more specific markers for MSC together with new technological advances will contribute to the development of the desired ES GEM for ES. This development could contribute to resolving many questions, such as the cell of origin and the role played by EWS/ETS genes in the pathogenesis of EFT; furthermore, it could facilitate new drug and treatment assays.
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